BMO Capital Reiterates Pfizer (PFE) at Ourperform, $76 PT, Sees etrasimod Better Positioned vs BMY's Zeposia
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $76.00 price target on Pfizer (NYSE: PFE) following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
